文献速递类风湿关节炎

类风湿关节炎中TNF抑制剂暴露与心肌梗死发生率和严重程度的关系

Relationship between exposure to tumour necrosis factor inhibitor therapy and incidence and severity of myocardial infarction in patients with rheumatoid arthritis.
PubMed 文献 · Ann Rheum Dis · 2017-01-10

该研究基于英国风湿病学会生物制剂注册队列,比较接受TNF抑制剂(TNFi)与合成改善病情抗风湿药(sDMARD)治疗的类风湿关节炎(RA)患者的心肌梗死(MI)风险与严重程度。结果显示,TNFi组经倾向评分校正后的MI风险显著低于sDMARD组(HR 0.61,95%CI 0.41–0.89),两组MI严重程度及梗死后6个月死亡率无显著差异。

要点

  • TNFi治疗与RA患者中MI风险降低相关(校正HR 0.61,95%CI 0.41–0.89)。
  • 两组MI严重程度及梗死后6个月死亡率无统计学显著差异。
  • 结论基于中位随访3.5年(sDMARD组)与5.3年(TNFi组)的观察性队列。

核心结论

  • 在中短期随访中,接受TNFi治疗的RA患者MI风险低于接受sDMARD治疗者。
  • TNFi可能通过直接作用于动脉粥样硬化过程或更好控制疾病活动而降低MI风险。

研究设计与样本

  • 研究纳入2001至2009年英国风湿病学会类风湿关节炎生物制剂注册中起始TNFi(依那西普/英夫利西单抗/阿达木单抗)的RA患者及未使用生物制剂的sDMARD对照队列。
  • 所有患者通过医师和患者问卷及国家死亡登记链接随访,并链接至国家心肌缺血审计项目(MINAP)以验证MI住院事件。
  • 采用倾向评分十分位校正的Cox回归比较首次MI风险,用描述性统计比较MI表型与严重程度,用逻辑回归比较MI后6个月死亡率。

主要发现

  • TNFi组相对sDMARD组的倾向评分校正MI风险比(HR)为0.61(95%CI 0.41–0.89)。
  • 两组间MI严重程度或死亡率未见统计学显著差异。

临床怎么用

  • 对于RA患者,使用TNFi可能不仅控制关节病情,还与降低MI风险相关。
  • 临床决策时可结合患者心血管风险综合评估TNFi的获益。

局限性

  • 原文未报告局限性内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Patients with rheumatoid arthritis (RA) are at increased risk of myocardial infarction (MI) compared with subjects without RA, with the increased risk driven potentially by inflammation. Tumour necrosis factor inhibitors (TNFi) may modulate the risk and severity of MI. We compared the risk and severity of MI in patients treated with TNFi with that in those receiving synthetic disease-modifying antirheumatic drugs (sDMARDs). METHODS: This analysis included patients with RA recruited from 2001 to 2009 to the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis starting TNFi (etanercept/infliximab/adalimumab) and a biologic-naïve comparator cohort receiving sDMARD. All patients were followed via physician and patient questionnaires and national death register linkage. Additionally, all patients were linked to the Myocardial Ischaemia National Audit Project, a national registry of hospitalisations for MI. Patients were censored at first verified MI, death, 90 days following TNFi discontinuation, last physician follow-up or 20 April 2010, whichever came first. The risk of first MI was compared between cohorts using COX regression, adjusted with propensity score deciles (PD). MI phenotype and severity were compared using descriptive statistics. 6-month mortality post MI was compared using logistic regression. RESULTS: 252 verified first MIs were analysed: 58 in 3058 patients receiving sDMARD and 194 in 11 200 patients receiving TNFi (median follow-up per person 3.5 years and 5.3 years, respectively). The PD-adjusted HR of MI in TNFi referent to sDMARD was 0.61 (95% CI 0.41 to 0.89). No statistically significant differences in MI severity or mortality were observed between treatment groups. CONCLUSIONS: Patients with RA receiving TNFi had a decreased risk of MI compared with patients with RA receiving sDMARD therapy over the medium term. This might be attributed to a direct action of TNFi on the atherosclerotic process or better overall disease control.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Low AS, Symmons DP, Lunt M, et al. Relationship between exposure to tumour necrosis factor inhibitor therapy and incidence and severity of myocardial infarction in patients with rheumatoid arthritis. Ann Rheum Dis. 2017. PMID: 28073800. doi:10.1136/annrheumdis-2016-209784

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。